Programmed death protein 1 inhibitors making inroads in multiple cancers

J Natl Cancer Inst. 2015 May 9;107(5):djv141. doi: 10.1093/jnci/djv141. Print 2015 May.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Biomarkers, Tumor / analysis
  • Combined Modality Therapy
  • Drug Approval
  • Humans
  • Immunotherapy / methods
  • Melanoma / drug therapy
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Skin Neoplasms / drug therapy
  • United States
  • United States Food and Drug Administration

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab